BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 12654753)

  • 1. Comparative distribution of azithromycin in lung tissue of patients given oral daily doses of 500 and 1000 mg.
    Danesi R; Lupetti A; Barbara C; Ghelardi E; Chella A; Malizia T; Senesi S; Angeletti CA; Del Tacca M; Campa M
    J Antimicrob Chemother; 2003 Apr; 51(4):939-45. PubMed ID: 12654753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of azithromycin in serum, bronchial washings, alveolar macrophages and lung tissue following a single oral dose of extended or immediate release formulations of azithromycin.
    Lucchi M; Damle B; Fang A; de Caprariis PJ; Mussi A; Sanchez SP; Pasqualetti G; Del Tacca M
    J Antimicrob Chemother; 2008 Apr; 61(4):884-91. PubMed ID: 18252692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations.
    Zhanel GG; DeCorby M; Noreddin A; Mendoza C; Cumming A; Nichol K; Wierzbowski A; Hoban DJ
    J Antimicrob Chemother; 2003 Jul; 52(1):83-8. PubMed ID: 12775677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of azithromycin in lung tissue, bronchial washing, and plasma in patients given multiple oral doses of 500 and 1000 mg daily.
    Di Paolo A; Barbara C; Chella A; Angeletti CA; Del Tacca M
    Pharmacol Res; 2002 Dec; 46(6):545-50. PubMed ID: 12457629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Azithromycin iv pharmacodynamic parameters predicting Streptococcus pneumoniae killing in epithelial lining fluid versus serum: an in vitro pharmacodynamic simulation.
    Sevillano D; Alou L; Aguilar L; Echevarría O; Giménez MJ; Prieto J
    J Antimicrob Chemother; 2006 Jun; 57(6):1128-33. PubMed ID: 16617063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.
    Girard D; Finegan SM; Dunne MW; Lame ME
    J Antimicrob Chemother; 2005 Aug; 56(2):365-71. PubMed ID: 16002421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of azithromycin after single- and multiple-doses in children.
    Stevens RC; Reed MD; Shenep JL; Baker DK; Foulds G; Luke DR; Blumer JL; Rodman JH
    Pharmacotherapy; 1997; 17(5):874-80. PubMed ID: 9324176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioavailability and pharmacokinetic comparison between generic and branded azithromycin capsule: a randomized, double-blind, 2-way crossover in healthy male Thai volunteers.
    Boonleang J; Panrat K; Tantana C; Krittathanmakul S; Jintapakorn W
    Clin Ther; 2007 Apr; 29(4):703-10. PubMed ID: 17617293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Preparation of lung targeting azithromycin liposomes and its tissue distribution in mice].
    Wang JS; Zhu JB; Lu RQ; Shen W
    Yao Xue Xue Bao; 2005 Mar; 40(3):274-8. PubMed ID: 15952603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue disposition of azithromycin after intravenous and intramuscular administration to rabbits.
    Cárceles CM; Fernández-Varón E; Marín P; Escudero E
    Vet J; 2007 Jul; 174(1):154-9. PubMed ID: 16904354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of lung tissue and hilar lymph node concentrations of azithromycin.
    Cazzola M; Siniscalchi C; Vinciguerra A; Santangelo G; Matera MG; Rossi F
    Int J Clin Pharmacol Ther; 1994 Feb; 32(2):88-91. PubMed ID: 8004364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of azithromycin in plasma and sinus mucosal tissue following administration of extended-release or immediate-release formulations in adult patients with chronic rhinosinusitis.
    Fang AF; Palmer JN; Chiu AG; Blumer JL; Crownover PH; Campbell MD; Damle BD
    Int J Antimicrob Agents; 2009 Jul; 34(1):67-71. PubMed ID: 19307106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease.
    Conte JE; Golden JA; McIver M; Little E; Zurlinden E
    Int J Antimicrob Agents; 2007 Nov; 30(5):422-7. PubMed ID: 17716873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of azithromycin after i.v. and i.m. administration to sheep.
    Cárceles CM; Font A; Escudero E; Espuny A; Marín P; Fernández-Varón E
    J Vet Pharmacol Ther; 2005 Oct; 28(5):475-9. PubMed ID: 16207311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of azithromycin in plasma, blood, polymorphonuclear neutrophils and sputum during long-term therapy in patients with cystic fibrosis.
    Wilms EB; Touw DJ; Heijerman HG
    Ther Drug Monit; 2006 Apr; 28(2):219-25. PubMed ID: 16628134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of azithromycin after intravenous and intramuscular administration to goats.
    Cárceles CM; Font A; Espuny A; Fernández-Varón E; Serrano JM; Escudero E
    J Vet Pharmacol Ther; 2005 Feb; 28(1):51-5. PubMed ID: 15720515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae.
    Deryke CA; Du X; Nicolau DP
    J Antimicrob Chemother; 2006 Sep; 58(3):601-9. PubMed ID: 16857688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sinus fluid penetration of oral clarithromycin and azithromycin in patients with acute rhinosinusitis.
    Margaritis VK; Ismailos GS; Naxakis SS; Mastronikolis NS; Goumas PD
    Am J Rhinol; 2007; 21(5):574-8. PubMed ID: 17999793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP).
    Noreddin AM; Marras TK; Sanders K; Chan CK; Hoban DJ; Zhanel GG
    Int J Antimicrob Agents; 2004 Nov; 24(5):479-84. PubMed ID: 15519481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of gastric bypass surgery on azithromycin oral bioavailability.
    Padwal RS; Ben-Eltriki M; Wang X; Langkaas LA; Sharma AM; Birch DW; Karmali S; Brocks DR
    J Antimicrob Chemother; 2012 Sep; 67(9):2203-6. PubMed ID: 22577100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.